Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Fineline Cube Mar 26, 2026

Partners United Laboratories International Holdings Ltd (HKG: 3933) and Novo Nordisk (NYSE: NVO) announced positive...

Company

Ascentage Pharma 2025 Revenue RMB 574M – Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches

Fineline Cube Mar 26, 2026

Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) reported 2025 financial results, with revenue declining...

Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced a definitive agreement to acquire Terns Pharmaceuticals,...

Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026

Daiichi Sankyo Co., Ltd. (TYO: 4568) announced a strategic partnership with Tempus AI, Inc., a...

Company

Hengrui Pharma 2025 Revenue RMB 31.6B – Innovative Drugs Drive 58% of Sales, Out-Licensing Hits RMB 3.4B

Fineline Cube Mar 26, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) reported 2025 annual results, with operating...

Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic partnership with SHL Medical, a Switzerland-based...

Company

XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M

Fineline Cube Mar 26, 2026

QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., reported 2025 financial results, achieving first annual...

Company

Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year

Fineline Cube Mar 26, 2026

Everest Medicines (HKG: 1952) reported 2024 financial results, with revenue skyrocketing 142% YoY to RMB...

Company Drug

CStone’s Sugemalimab Wins ESMO [I, A] Recommendation – PD-L1 Inhibitor Targets Stage III NSCLC Consolidation Therapy in Europe

Fineline Cube Mar 26, 2026

CStone Pharmaceuticals (HKG: 2616) announced that sugemalimab received a class recommendation in the...

Company Drug

SinoMab BioScience Reports Positive Phase I Bridging Data for SM17 – First-in-Class IL-25 Receptor Antibody Advances Route Conversion

Fineline Cube Mar 26, 2026

SinoMab BioScience Ltd (HKG: 3681) announced positive readouts from a Phase I bridging study in...

Company

InnoCare Pharma Reports 2025 Profitability – Revenue Surges 135% to RMB 2.37B on Global BD Success

Fineline Cube Mar 26, 2026

InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with...

Company Deals

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Fineline Cube Mar 26, 2026

Insilico Medicine (HKG: 3696) and Tenacia Biotechnology, a central nervous system (CNS) specialist, announced an...

Company Deals

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

Fineline Cube Mar 25, 2026

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420) announced a licensing agreement with Shanghai ScienPharm, obtaining...

Company Deals

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Fineline Cube Mar 25, 2026

Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ:...

Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Fineline Cube Mar 25, 2026

Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) announced the initiation of a Phase I clinical...

Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Fineline Cube Mar 25, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that GenSci128 received Orphan...

Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Fineline Cube Mar 25, 2026

China’s National Health Commission (NHC) announced that chikungunya fever and severe fever with thrombocytopenia syndrome...

Company Drug

Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication

Fineline Cube Mar 25, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced NMPA clinical trial approval to initiate a study...

Company Drug

Clover Bio Reports Positive SCB‑1019 Phase I Data – RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy

Fineline Cube Mar 25, 2026

Clover Biopharmaceuticals Ltd. (HKG: 2197) announced additional positive Phase I data from its US clinical...

Company

Merck KGaA Inaugurates China R&D Center – Beijing BioPark Hub Targets First‑Tier Global Drug Launch Status

Fineline Cube Mar 25, 2026

Merck KGaA (ETR: MRK) announced the inauguration of its China R&D Center at the BioPark...

Posts pagination

1 … 68 69 70 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.